These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 19716365

  • 1. Future neuroprotective strategies.
    Sättler MB, Bähr M.
    Exp Neurol; 2010 Sep; 225(1):40-7. PubMed ID: 19716365
    [Abstract] [Full Text] [Related]

  • 2. The future of multiple sclerosis treatment.
    Cohen JA.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [Abstract] [Full Text] [Related]

  • 3. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis.
    Wang D, Ayers MM, Catmull DV, Hazelwood LJ, Bernard CC, Orian JM.
    Glia; 2005 Aug 15; 51(3):235-40. PubMed ID: 15812814
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: clinical and histopathological evaluation.
    Stojkov D, Lavrnja I, Pekovic S, Dacic S, Bjelobaba I, Mostarica-Stojkovic M, Stosic-Grujicic S, Jovanovic S, Nedeljkovic N, Rakic L, Stojiljkovic M.
    J Neurol Sci; 2008 Apr 15; 267(1-2):76-85. PubMed ID: 17996253
    [Abstract] [Full Text] [Related]

  • 5. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
    Mirowska-Guzel D.
    Immunopharmacol Immunotoxicol; 2009 Apr 15; 31(1):32-8. PubMed ID: 18792835
    [Abstract] [Full Text] [Related]

  • 6. Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis.
    Hasseldam H, Johansen FF.
    Neuroimmunomodulation; 2010 Apr 15; 17(4):252-64. PubMed ID: 20203531
    [Abstract] [Full Text] [Related]

  • 7. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets.
    Aktas O, Waiczies S, Zipp F.
    J Neuroimmunol; 2007 Mar 15; 184(1-2):17-26. PubMed ID: 17222462
    [Abstract] [Full Text] [Related]

  • 8. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis.
    Diem R, Sättler MB, Merkler D, Demmer I, Maier K, Stadelmann C, Ehrenreich H, Bähr M.
    Brain; 2005 Feb 15; 128(Pt 2):375-85. PubMed ID: 15601662
    [Abstract] [Full Text] [Related]

  • 9. Neurodegeneration in autoimmune CNS inflammation.
    Herz J, Zipp F, Siffrin V.
    Exp Neurol; 2010 Sep 15; 225(1):9-17. PubMed ID: 19961850
    [Abstract] [Full Text] [Related]

  • 10. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC, Hartung HP.
    Exp Neurol; 2007 Jan 15; 203(1):1-4. PubMed ID: 17069803
    [No Abstract] [Full Text] [Related]

  • 11. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
    Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T.
    Pharmacol Ther; 2010 Apr 15; 126(1):82-93. PubMed ID: 20122960
    [Abstract] [Full Text] [Related]

  • 12. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R.
    J Neurol Sci; 2009 Dec 15; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [Abstract] [Full Text] [Related]

  • 13. FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis.
    Gold BG, Voda J, Yu X, McKeon G, Bourdette DN.
    J Neurosci Res; 2004 Aug 01; 77(3):367-77. PubMed ID: 15248293
    [Abstract] [Full Text] [Related]

  • 14. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
    Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, Black JA, Newcombe J, Cuzner ML, Waxman SG.
    Glia; 2005 Jan 15; 49(2):220-9. PubMed ID: 15390090
    [Abstract] [Full Text] [Related]

  • 15. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis.
    Gresle MM, Shaw G, Jarrott B, Alexandrou EN, Friedhuber A, Kilpatrick TJ, Butzkueven H.
    J Neurosci Res; 2008 Dec 15; 86(16):3548-55. PubMed ID: 18709652
    [Abstract] [Full Text] [Related]

  • 16. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models.
    Lassmann H.
    Exp Neurol; 2010 Sep 15; 225(1):2-8. PubMed ID: 19840788
    [Abstract] [Full Text] [Related]

  • 17. [Recent advances in pathogenesis and therapy of multiple sclerosis].
    Linker RA, Stadelmann C, Diem R, Bähr M, Brück W, Gold R.
    Fortschr Neurol Psychiatr; 2005 Dec 15; 73(12):715-27. PubMed ID: 16355314
    [Abstract] [Full Text] [Related]

  • 18. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Vogt J, Paul F, Aktas O, Müller-Wielsch K, Dörr J, Dörr S, Bharathi BS, Glumm R, Schmitz C, Steinbusch H, Raine CS, Tsokos M, Nitsch R, Zipp F.
    Ann Neurol; 2009 Sep 15; 66(3):310-22. PubMed ID: 19798635
    [Abstract] [Full Text] [Related]

  • 19. New directions in MS therapeutics: vehicles of hope.
    Fox RJ, Ransohoff RM.
    Trends Immunol; 2004 Dec 15; 25(12):632-6. PubMed ID: 15530830
    [Abstract] [Full Text] [Related]

  • 20. [Neuronal injury in multiple sclerosis].
    Correale J, Meli F, Ysrraelit C.
    Medicina (B Aires); 2006 Dec 15; 66(5):472-85. PubMed ID: 17137182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.